Table 3.

Association between prognostic value of PRDXs mRNA expression and various chemotherapies in BrCa

Chemotherapies	Cases	HR	95% CI	P value	Cases	HR	95% CI	P value
	OS				RFS
PRDX1
Adjuvant chemotherapy	163	1.85	1.01–3.40	0.044	594	1.05	0.78–1.42	0.734
Neoadjuvant chemotherapy	156	0.74	0.34–1.60	0.448	223	1.19	0.69–2.03	0.539
Non-chemotherapy	549	1.13	0.79–1.60	0.502	1873	1.22	1.03–1.44	0.019
PRDX2
Adjuvant chemotherapy	163	2.02	1.09–3.73	0.023	594	1.33	0.98–1.80	0.064
Neoadjuvant chemotherapy	156	1.41	0.66–3.02	0.375	223	1.24	0.72–2.16	0.438
Non-chemotherapy	549	1.14	0.80–1.62	0.483	1873	1.07	0.90–1.26	0.444
PRDX3
Adjuvant chemotherapy	163	2.03	1.10–3.73	0.021	594	0.80	0.59–1.08	0.148
Neoadjuvant chemotherapy	156	1.05	0.49–2.23	0.906	223	0.95	0.55–1.65	0.851
Non-chemotherapy	549	0.79	0.56–1.12	0.185	1873	0.84	0.71–1.00	0.043
PRDX4
Adjuvant chemotherapy	163	1.97	1.07–3.65	0.027	594	1.02	0.75–1.38	0.906
Neoadjuvant chemotherapy	156	0.68	0.31–1.48	0.325	223	1.19	0.69–2.07	0.529
Non-chemotherapy	549	1.28	0.90–1.82	0.177	1873	1.37	1.16–1.62	< 0.001
PRDX5
Adjuvant chemotherapy	0	1.09	0.58–2.06	0.790	255	0.50	0.30–0.81	0.005
Neoadjuvant chemotherapy	107	0.67	0.24–1.89	0.446	111	1.22	0.58–2.57	0.595
Non-chemotherapy	0	0.58	0.29–1.15	0.117	243	0.66	0.38–1.14	0.131
PRDX6
Adjuvant chemotherapy	163	0.86	0.48–1.56	0.625	594	1.10	0.81–1.49	0.532
Neoadjuvant chemotherapy	156	0.72	0.33–1.55	0.395	223	1.09	0.63–1.88	0.769
Non-chemotherapy	549	1.33	0.94–1.88	0.110	1873	1.19	1.00–1.40	0.044